KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Research & Development (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Research & Development for 7 consecutive years, with $50.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 10000.0% to $50.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $401.5 million through Dec 2025, up 19975.0% year-over-year, with the annual reading at $452.0 million for FY2025, 22500.0% up from the prior year.
  • Research & Development hit $50.5 million in Q4 2025 for Royalty Pharma, roughly flat from $50.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $250.0 million in Q2 2025 to a low of $500000.0 in Q1 2023.
  • Historically, Research & Development has averaged $41.6 million across 5 years, with a median of $14.3 million in 2021.
  • Biggest five-year swings in Research & Development: tumbled 99.5% in 2023 and later skyrocketed 49900.0% in 2025.
  • Year by year, Research & Development stood at $103.8 million in 2021, then tumbled by 51.35% to $50.5 million in 2022, then crashed by 99.01% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then surged by 10000.0% to $50.5 million in 2025.
  • Business Quant data shows Research & Development for RPRX at $50.5 million in Q4 2025, $50.5 million in Q3 2025, and $250.0 million in Q2 2025.